Select: Molecular Pathology of Alzheimer's Disease b-amyloid accumulation is a hallmark of Alzheimer's disease pathology, but how does it cause cognitive impairment? New findings described in this issue's Select examine how b-amyloid impacts signaling events at the synapse at early stages of disease progression. And at later stages, one study suggests that Alzheimer's patients exhibit a pronounced deficiency in their capacity to metabolize b-amyloid.
Caspase-3 Gets an Early Start
In Alzheimer's disease, impaired performance on cognitive tasks precedes the wholesale loss of neurons, suggesting that synaptic dysfunction is to blame for early symptoms. Using a mouse model that expresses a mutant allele of human amyloid precursor protein found in familial Alzheimer's disease (Tg2576 mice), D'Amelio et al. (2011) examine the onset of memory decline and correlate its timing with molecular changes at the synapse. They reveal that caspase-3 activation is elevated in the transgenic mice at the onset of synaptic dysfunction in the hippocampus. Although the caspase-3 activation is above baseline, it is not high enough to trigger apoptosis and is localized to the postsynaptic compartment. Caspase-3 activity is a known activator of the protein phosphatase calcineurin, which in turn dephosphorylates the AMPA receptor subunit GluR1 to regulate its subcellular distribution. Thus, in the current work, the authors provide evidence linking the elevation in caspase-3 activity to a cascade of events that culminate in a reduction in the level of AMPA receptors at postsynaptic densities. As further evidence in support of the model and looking forward to future therapeutic possibilities, the authors show that both the molecular and cognitive phenotypes of Tg2576 mice are improved by the administration of caspase-3 inhibitors. A question left open for future work is to establish what processes downstream of b-amyloid production contribute to elevated caspase-3 activation. D' Amelio et al. (2011). Nat. Neurosci. 14, 69-76. b-amyloid induces AMPA receptor (AMPAr) dephosphorylation via a pathway involving caspase-3 (Casp-3) and calcineurin (CaN). Image courtesy of F. Cecconi.
Where and When Does Tau Go Wrong?
Tau is a core component of neurofibrillary tangles, one of the hallmarks of Alzheimer's disease and other dementias, but when and where does altered tau function have its detrimental effects? According to new findings by Hoover et al. (2010) , it is early, at synapses, and is independent of neurodegeneration. The authors characterize mice expressing a human tau variant with a mutation associated with frontotemporal dementia (rTgP301L mice) and show that mutant tau is mislocalized to dendritic spines in the first few months of life. This is noteworthy, as the mislocalization occurs prior to the loss of synapses and neurons (which occur at later stages in this mouse model) yet coincides with the onset of impairment in cognitive tasks and synaptic plasticity. Probing the molecular basis for the dysfunction, the authors link the mislocalization phenotype to a reduction in AMPA and NMDA receptors in the postsynaptic membrane (see also the recent work of Ittner et al. Cell 142, 387-397). They further show that the mislocalization is dependent on tau phosphorylation. When 14 serines and threonines are mutated to mimic hyperphosphorylation, tau is mistargeted to dendritic spines, and when the same residues are mutated to alanines to block phosphorylation, the mislocalization is alleviated. These findings suggest that efforts to impede tau mislocalization at early stages of tauopathies might prevent some of their most debilitating outcomes, thus raising the question: what molecular mechanisms make phosphorylated tau prone to accumulation in dendritic spines? Hoover et al. (2010) . Neuron 68, 1067 Neuron 68, -1081 
Work Slowdown by the b-Amyloid Clean-Up Crew
Given that much of the emphasis in the Alzheimer's research community is placed on understanding the abberrant production of toxic oligomeric species of b-amyloid, the recent report by Mawuenyaga et al. (2010) casts the molecular pathology of the disease in an interesting and provocative light. By collecting cerebral spinal fluid from individuals infused with 13 C 6 -leucine to label newly synthesized proteins, the authors probed the rates of production and clearance of soluble b-amyloid. A comparison of control individuals and Alzheimer's patients surprisingly reveals that the rates of production of b-amyloid (both Ab40 and Ab42) are similar between the two groups. Instead, stark differences are observed in their respective rates of b-amyloid clearance, with late-onset Alzheimer's patients exhibiting a 30% decrease. The authors calculate that this diminishment of b-amyloid metabolism is consistent with a 10 year timeframe for the buildup of b-amyloid in the disease. An intriguing question now is to determine what might account for the decreased capacity for soluble b-amyloid clearance in Alzheimer's patients. Also, how early in the disease process is altered b-amyloid metabolism a factor? Does this point the way to new therapeutic approaches? If so, what existing soluble b-amyloid clean-up pathways in the central nervous systems might be ramped up to help counter its toxic accumulation? Mawuenyega et al. (2010) . Science 330, 1774. A theoretical graph shows the effects of increased production (red) or decreased clearance (blue) as possibilities for altered b-amyloid metabolism. Image courtesy of R. Bateman.
